57 related articles for article (PubMed ID: 12060606)
1. New HER2-directed therapies for breast cancer. Commentary re: C. I. Spiridon et al., Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity. Clin. Cancer Res., 8: 1720-1730, 2002.
Frankel AE
Clin Cancer Res; 2002 Jun; 8(6):1699-701. PubMed ID: 12060606
[No Abstract] [Full Text] [Related]
2. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
Spiridon CI; Ghetie MA; Uhr J; Marches R; Li JL; Shen GL; Vitetta ES
Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609
[TBL] [Abstract][Full Text] [Related]
3. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002.
Siwak DR; Tari AM; Lopez-Berestein G
Clin Cancer Res; 2002 Apr; 8(4):955-6. PubMed ID: 11948099
[No Abstract] [Full Text] [Related]
4. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
Borghaei H; Alpaugh RK; Bernardo P; Palazzo IE; Dutcher JP; Venkatraj U; Wood WC; Goldstein L; Weiner LM
J Immunother; 2007; 30(4):455-67. PubMed ID: 17457220
[TBL] [Abstract][Full Text] [Related]
5. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
6. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
[TBL] [Abstract][Full Text] [Related]
7. Commentary re: N. J. McCarthy et al., microvessel density, expression of estrogen receptor alpha, MIB-1, p53 and c-erbB-2 in inflammatory breast cancer. Clin. Cancer Res., 8: 3857-3862, 2002.
Colpaert CG; Vermeulen PB; Dirix LY; Van Marck EA
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3815-6; author reply 3816. PubMed ID: 14506176
[No Abstract] [Full Text] [Related]
8. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
[TBL] [Abstract][Full Text] [Related]
9. [New antibody for breast cancer therapy. Interview by Brigitte Schalhorn].
Eiermann W
Fortschr Med; 1998 Jun; 116(18-19):18. PubMed ID: 9691532
[No Abstract] [Full Text] [Related]
10. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.
Gao J; Kou G; Wang H; Chen H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y
Breast Cancer Res Treat; 2009 May; 115(1):29-41. PubMed ID: 18481173
[TBL] [Abstract][Full Text] [Related]
11. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
Czerniecki BJ; Koski GK; Koldovsky U; Xu S; Cohen PA; Mick R; Nisenbaum H; Pasha T; Xu M; Fox KR; Weinstein S; Orel SG; Vonderheide R; Coukos G; DeMichele A; Araujo L; Spitz FR; Rosen M; Levine BL; June C; Zhang PJ
Cancer Res; 2007 Feb; 67(4):1842-52. PubMed ID: 17293384
[TBL] [Abstract][Full Text] [Related]
12. A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth.
Kawa S; Matsushita H; Ohbayashi H; Semba K; Yamamoto T
Biochem Biophys Res Commun; 2009 Jul; 384(3):329-33. PubMed ID: 19409371
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
[TBL] [Abstract][Full Text] [Related]
14. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase.
Montgomery RB; Makary E; Schiffman K; Goodell V; Disis ML
Cancer Res; 2005 Jan; 65(2):650-6. PubMed ID: 15695410
[TBL] [Abstract][Full Text] [Related]
15. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
Savellano MD; Pogue BW; Hoopes PJ; Vitetta ES; Paulsen KD
Cancer Res; 2005 Jul; 65(14):6371-9. PubMed ID: 16024640
[TBL] [Abstract][Full Text] [Related]
16. The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature.
Fetsch PA; Abati A
Diagn Cytopathol; 2007 Jun; 35(6):319-28. PubMed ID: 17497656
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A
Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031
[TBL] [Abstract][Full Text] [Related]
18. Generation of HER2 monoclonal antibodies using epitopes of a rabbit polyclonal antibody.
Hu FJ; Uhlen M; Rockberg J
N Biotechnol; 2014 Jan; 31(1):35-43. PubMed ID: 24120493
[TBL] [Abstract][Full Text] [Related]
19. Should we treat HER, too?
Hayes DF
J Clin Oncol; 1996 Mar; 14(3):697-9. PubMed ID: 8622013
[No Abstract] [Full Text] [Related]
20. Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth.
Emde A; Pradeep CR; Ferraro DA; Ben-Chetrit N; Sela M; Ribba B; Kam Z; Yarden Y
Oncogene; 2011 Apr; 30(14):1631-42. PubMed ID: 21132012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
